Drug Trial Radar · NCT06021054
An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
188
Actual
Start
Nov 1, 2023
Primary completion
Nov 4, 2024
Study completion Jul 25, 2025
Sponsor
- Lead sponsor
- Viridian Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chronic thyroid eye disease (TED).
Conditions
- Thyroid Eye Disease
Interventions
VeligrotugDrug
5 IV Infusions of veligrotug 10 mg/kg
PlaceboDrug
5 IV Infusions of veligrotug matched placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proptosis Responder Rate (PRR) in the Most Proptotic Eye as Measured by ExophthalmometerTime frame: Baseline to Week 15
Locations
57 sites in 9 countries. Site status is shown where the registry gives one.
Advancing Research International, LLC
Los Angeles, California
USC Roski Eye Institute
Los Angeles, California
Amy Patel Jain, MD
Newport Beach, California
Stanford Byers Eye Institute
Palo Alto, California
Cockerham Eye Consultants, PC
San Diego, California
Bascom Palmer Eye Institute - Ophthalmology - Miami
Miami, Florida
Sarasota Retina Institute
Sarasota, Florida
Northwestern University
Chicago, Illinois
Family Eye Physicians, Ltd
Oak Lawn, Illinois
Massachusetts Eye and Ear
Boston, Massachusetts
Ophthalmic Consultants of Boston
Boston, Massachusetts
Michigan State University, Department of Neurology
East Lansing, Michigan
Kahana Oculoplastic and Orbital Surgery
Livonia, Michigan
Washington University School of Medicine in St Louis - Ophthalmology
St Louis, Missouri
Steven Leibowitz, MD.
Las Vegas, Nevada
Rutgers - New Jersey Medical School
Newark, New Jersey
The Center for Eye and Facial Plastic Surgery
Somerset, New Jersey
Department of Ophthalmology, University of Pennsylvania
Philadelphia, Pennsylvania
Wills Eye Hospital
Philadelphia, Pennsylvania
Baylor College of Medicine (BCM) - Ophthalmology
Houston, Texas
Neuro Eye Clinical Trials
Houston, Texas
University of Vermont Medical Center
Burlington, Vermont
Harborview Medical Center
Seattle, Washington
North Shore Private Hospital
Saint Leonards, New South Wales, Australia
CHU Angers
Angers, France
CHU de Bordeaux - Hôpital Saint-André
Bordeaux, France
Centre Hospitalier Universitaire De Nantes - G. R. Laennec
Nantes, France
CH Nice
Nice, France
Charité - Universitätsmedizin Berlin KöR
Berlin, Germany
Universitätsklinikum Essen AöR
Essen, Germany
University Medical Center Freiburg
Freiburg im Breisgau, Germany
Universitätsmedizin Göttingen
Göttingen, Germany
Budapest Retina Intezet
Budapest, Hungary
Ganglion Orvosi Kozpont
Pécs, Hungary
Pecsi Tudomanyegyetem Klinikai Kozpont Szemeszeti Klinika
Pécs, Hungary
Uniwersytecki Szpital Kliniczny w Bialymstoku
Bialystok, Poland
Oculomedica Sp. z o.o.
Bialystok, Poland
Optimum Profesorskie Centrum Okulistyki Sp. z o.o.
Gdansk, Poland
Centrum Medyczne Pulawska Sp. z o.o.
Piaseczno, Poland
Centrum Medyczne Piasta 47 sp. z o.o.
Wałbrzych, Poland
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.